Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel
Clopidogrel is the most studied P2Y12 receptor blocker and still has no alternative in a number of categories of ACS patients in whom ticagrelor or prasugrel have not been studied or their use is associated with an unacceptably high risk of bleeding. The review is devoted to a detailed consideration...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2022-06-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/269 |